Atosiban

Drug Profile

Atosiban

Alternative Names: Antocile; Antocin; Antocin II; CAP 440; CAP 476; deTVT; dTVT; F 314; ORF 22164; RWJ 22164; Tractocile

Latest Information Update: 08 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; University of Turin
  • Class Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Preterm labour
  • Discontinued Cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Jul 2001 A study has been added to the adverse events and Women's Health therapeutic trials sections
  • 03 Jul 2000 Three multicentre studies have been added to the Women's Health therapeutic trials section ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top